Clinical Trial Update: Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated pevonedistat in combination with irinotecan and temozolomide in patients with recurrent or refractory solid tumors and lymphoma; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasms
• Lymphoma
• Solid Tumors

Drugs mentioned

• Irinotecan (Irinotecan)
• Pevonedistat (pevonedistat)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Children's Oncology Group | Conditions: Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm | Phase 1 | Status: COMPLETED | Results posted: 2022-09-23